A Phase 3 interventional study of Lumateperone in Major Depressive Disorder, sponsored by Intra-Cellular Therapies, Inc.. Completed at 109 sites in 11 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-03.
Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Depressive Disorder, Major by Johnson & Johnson — 5 open to participants now, 5 under way, 5 of them phase 3. Depressive Disorder, Major · Johnson & Johnson.
Among the 59 studies in Depressive Disorder, Major by Johnson & Johnson, this one is the 2nd largest by enrollment of the 52 interventional ones that give a count, is one of 6 that started in 2021, is one of 23 in phase 3, and was the 44th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →5 of the 59 studies in Depressive Disorder, Major by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, Argentina, Brazil and 4 more countries
Ages 18–74
Janssen Research & Development, LLC · Sites in United States, Brazil, Hungary and 4 more countries
Ages 12–17
Janssen Research & Development, LLC · Sites in United States, Argentina, Brazil and 13 more countries
Ages 18–74
Intra-Cellular Therapies, Inc. · Sites in United States, Bulgaria, France and 4 more countries
Ages 18–65
Intra-Cellular Therapies, Inc.
Ages 18–74
By country, each count listing its studies:
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 6 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 812 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 203 across the 52 interventional studies, 136 across the 7 observational. Of the 53 that completed or were terminated, 26 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Intra-Cellular Therapies, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Intra-Cellular Therapies, Inc. is the lead sponsor of 41 studies on the registry; 12 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 11 (46%) have results posted.
2 of the studies in Depressive Disorder, Major by Johnson & Johnson that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
| NCT05850689Phase 3Intra-Cellular Therapies, Inc.Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | 2027-04-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 59 studies in Depressive Disorder, Major by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, open-label, fixed dose, 26 week study of patients with MDD. Eligible patients from the lead-in studies will enter the Open-label Safety Study at the Screening/Baseline Visit (Visit 1/Day 1), at which point patient eligibility will be assessed and informed consent obtained.
At the Screening/Baseline Visit (Visit 1/Day 1), which is the same visit as Visit 8/Day 43 of the lead-in study, eligible patients will receive open-label lumateperone 42 mg once daily for approximately 26 weeks. Patients will continue their background ADT from the lead-in study. Patients will be seen for weekly visits through Visit 5/Week 4. Thereafter, visits will occur every two weeks. A Safety Follow-up visit will occur on Visit 17/Day 197, approximately 2 weeks after the last dose of open-label lumateperone 42 mg.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during the course of her/his participation in the study or is considered to be an imminent danger to her/himself or others, and/or:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Lumateperone
Lumateperone 42 mg capsules administered orally, once daily
The Number and Percentage of Patients Reporting Treatment Emergent Adverse Events
An AE that occurs during the Open-label Treatment Period will be considered a treatment-emergent AE (TEAE) if it was not present before the date of the first dose of open-label lumateperone or was present before the date of the first dose of open-label lumateperone but changed in severity during the Open-label Treatment Period.
Time frame: 26 weeks
Change From Baseline in One of the 6 Week Double-blind Lead-in Studies (NCT04985942 & NCT05061706) to the End of the Open-Label Treatment Period (a Combined Total of up to 32 Weeks) in the Montgomery-Åsberg Depression Rating Scale
The MADRS is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.
Time frame: 32 weeks
Change From Baseline in One of the 6 Week Double-blind Lead-in Studies (NCT04985942 & NCT05061706) to the End of the Open-Label Treatment Period (a Combined Total of up to 32 Weeks) in the Clinical Global Impression Scale-Severity
The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not ta all ill) to 7 (among the most extremely ill patients).
Time frame: 32 weeks
| Milestone | Lumateperone 42 mg |
|---|---|
| Started | 809 |
| Completed | 684 |
| Not completed | 125 |
| Withdrew: Adverse event | 60 |
| Withdrew: Death | 1 |
| Withdrew: Lack of efficacy | 7 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Pregnancy | 1 |
| Withdrew: Protocol violation | 8 |
| Withdrew: Withdrawal by subject | 41 |
| Withdrew: Site closure | 2 |
An AE that occurs during the Open-label Treatment Period will be considered a treatment-emergent AE (TEAE) if it was not present before the date of the first dose of open-label lumateperone or was present before the date of the first dose of open-label lumateperone but changed in severity during the Open-label Treatment Period.
| Participants | Lumateperone 42 mg |
|---|---|
| The Number and Percentage of Patients Reporting Treatment Emergent Adverse Events | 548 |
The MADRS is a clinician-rated 10 item scale to assess depressive symptoms. Each item is rated on a 7-point scale from 0-6. The total score ranges from 0 to 60 with a higher score indicating increased severity of depressive symptoms.
| score on a scale | Lumateperone 42 mg |
|---|---|
| Change From Baseline in One of the 6 Week Double-blind Lead-in Studies (NCT04985942 & NCT05061706) to the End of the Open-Label Treatment Period (a Combined Total of up to 32 Weeks) in the Montgomery-Åsberg Depression Rating Scale | -21.7 ± 8.39 |
The CGI-S is a clinician-rated scale to assess a patient's overall mental health. The scale ranges from 1 (normal, not ta all ill) to 7 (among the most extremely ill patients).
| score on a scale | Lumateperone 42 mg |
|---|---|
| Change From Baseline in One of the 6 Week Double-blind Lead-in Studies (NCT04985942 & NCT05061706) to the End of the Open-Label Treatment Period (a Combined Total of up to 32 Weeks) in the Clinical Global Impression Scale-Severity | -2.5 ± 1.19 |
Collected over From signing ICF until end of study procedures (~28 weeks), including 26 weeks of open-label treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lumateperone 42 mg | 1/809 (0.1%) | 8/809 (1%) | 322/809 (39.8%) |
| Event | Lumateperone 42 mg |
|---|---|
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 2/809 |
| Alcohol PoisoningInjury, poisoning and procedural complications | 1/809 |
| ContusionInjury, poisoning and procedural complications | 1/809 |
| Spinal compression fractureInjury, poisoning and procedural complications | 1/809 |
| Biliary colicHepatobiliary disorders | 1/809 |
| Helicobacter gastritisInfections and infestations | 1/809 |
| Postmenopausal haemorrhageReproductive system and breast disorders | 1/809 |
| Event | Lumateperone 42 mg |
|---|---|
| HeadacheNervous system disorders | 134/809 |
| DizzinessNervous system disorders | 86/809 |
| Dry mouthGastrointestinal disorders | 65/809 |
| NauseaGastrointestinal disorders | 62/809 |
| SomnolenceNervous system disorders | 58/809 |
| DiarrhoeaGastrointestinal disorders | 50/809 |
| NasopharyngitisInfections and infestations | 42/809 |
| Age, Continuous(years) | Lumateperone 42 mg |
|---|---|
| Mean | 46.2 ± 12.22 |
| Sex: Female, Male(Participants) | Lumateperone 42 mg |
|---|---|
| Female | 549 |
| Male | 260 |
| Race/Ethnicity, Customized(Participants) | Lumateperone 42 mg |
|---|---|
| White | 703 |
| Black or African American | 37 |
| Asian | 61 |
| Native Hawaiian or Other Pacific Islander | 2 |
| Multiple | 4 |
| Other | 2 |
| Region of Enrollment(participants) | Lumateperone 42 mg |
|---|---|
| Sweden | 2 |
| Hungary | 15 |
| United States | 225 |
| Czechia | 95 |
| Poland | 147 |
| Slovakia | 32 |
| Bulgaria | 159 |
| Germany | 25 |
| India | 53 |
| Argentina | 56 |
Showing the first 100 of 109 sites across 11 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2021 to primary completion in Oct 2024, 36 months.
Results were first posted in Nov 2025, 1 year after primary completion.
Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 36 months is above that.
Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lumateperone
Intra-Cellular Therapies, Inc. →